Healthcare / Drug Manufacturers - Specialty & GenericKOSDAQ
$6000.00
-180.00 (-2.91%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-4.8B · quality 54.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
7/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$30.6B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-14.4%
↓Gross Margin
51.3%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-31.8%
FCF CAGR
—
FCF margin
-45.3%
FCF / Net income
0.64x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $16.71B · net income $-11.92B · FCF $-7.57B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $16.71B | $16.71B | $17.66B | $25.59B | $52.76B |
| Net Income | $-11.92B | $-11.92B | $-7.88B | $-1.38B | $1.59B |
| EBITDA | $-8.45B | $-8.45B | $-5.72B | $-97.9M | $2.62B |
| EPS | -2340.00 | -2340.00 | -1547.00 | -270.00 | 304.00 |
| Gross Margin | 51.3% | 51.3% | 41.4% | 62.1% | 69.2% |
| Operating Margin | -66.2% | -66.2% | -55.8% | -18.3% | -1.1% |
| Net Margin | -71.3% | -71.3% | -44.6% | -5.4% | 3.0% |
| Balance Sheet | |||||
| Debt/Equity | — | — | 0.00 | — | 0.00 |
| Current Ratio | 15.16 | 15.16 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-7.57B | $-7.57B | $-4.83B | $-4.43B | $-8.03B |
| Returns | |||||
| ROE | -14.4% | -14.4% | -8.3% | -1.3% | 1.5% |
| Valuation | |||||
| P/E | — | — | — | — | 58.55 |
| EV/EBITDA | — | — | — | — | 34.19 |
| P/B | 0.37 | 0.37 | 0.67 | 0.78 | 0.89 |
| Growth & Yield | |||||
| Revenue Growth | -5.4% | -5.4% | -31.0% | -51.5% | — |
| EPS Growth | -51.3% | -51.3% | -473.0% | -188.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-51.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-1547.00 → -2340.00
Residual
-51.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.